Supplementary Table 1s. Hazard ratio (HR) for reaching the primary endpoint according to treatment group and quintile of baseline serum urate (referenced to placebo-treated subjects in the lowest quintile).

Treatment group	Serum urate quintile	HR*	P-value
Double placebo	1	1.00 (Ref.)	--
	2	0.98	0.94
	3	0.79	0.43
	4	0.74	0.34
	5	0.55	0.07
α-Tocopherol-placebo	1	0.68	0.24
	2	0.75	0.37
	3	1.25	0.45
	4	0.63	0.18
	5	0.60	0.12
Deprenyl-placebo	1	0.58	0.07
	2	0.30	0.002
	3	0.43	0.03
	4	0.33	0.001
	5	0.26	<0.001
α-Tocopherol-deprenyl	1	0.29	0.006
	2	0.39	0.005
	3	0.40	0.01
	4	0.40	0.007
	5	0.29	<0.001

* Adjusted for age and gender.

Supplementary Table 2s. Hazard ratio (HR) for reaching endpoint according to treatment group and quintile of baseline CSF urate (referenced to placebo-treated subjects in the lowest quintile).

Treatment group	Serum urate quintile	HR*	P-value
Double placebo	1	1.00 (Ref.)	--
	2	0.65	0.16
	3	0.45	0.03
	4	0.94	0.83
	5	0.43	0.02
α-Tocopherol-placebo	1	0.80	0.48
	2	0.67	0.21
	3	0.71	0.31
	4	0.53	0.07
	5	0.67	0.20
Deprenyl-placebo	1	0.46	0.01
	2	0.36	0.004
	3	0.42	0.01
	4	0.26	<0.001
	5	0.18	<0.001
α-Tocopherol-deprenyl	1	0.25	0.001
	2	0.28	0.002
	3	0.23	<0.001
	4	0.45	0.02
	5	0.38	0.01

* Adjusted for age and gender.

Supplementary Table 3s. Annualized rate of UPDRS change according to treatment group and quintile of baseline serum urate.

Treatment group	Serum urate quintile	Mean UPDRS rate of change*	(S.E.)
Double placebo	1	25.34	(3.18)
	2	16.11	(3.53)
	3	16.82	(2.85)
	4	14.20	(3.09)
	5	10.93	(3.40)
α-Tocopherol-placebo	1	13.26	(3.10)
	2	18.80	(3.22)
	3	19.19	(3.23)
	4	13.07	(3.15)
	5	15.89	(3.32)
Deprenyl-placebo	1	8.38	(2.77)
	2	4.46	(3.69)
	3	5.93	(3.69)
	4	7.68	(3.00)
	5	1.00	(2.94)
α-Tocopherol-deprenyl	1	3.56	(3.28)
	2	4.46	(2.98)
	3	3.47	(3.68)
	4	7.03	(3.18)
	5	2.99	(3.33)

*Least squares means adjusted for age and gender.

Supplementary Table 4s. Annualized rate of UPDRS change according to treatment group and quintile of baseline CSF urate.

Treatment group	Serum urate quintile	Mean UPDRS rate of change*	(S.E.)
Double placebo	1	25.67	(3.60)
	2	18.90	(3.07)
	3	17.02	(3.95)
	4	15.01	(3.43)
	5	12.54	(3.64)
α-Tocopherol-placebo	1	17.57	(3.49)
	2	19.84	(3.47)
	3	18.84	(3.75)
	4	12.63	(3.62)
	5	17.07	(3.49)
Deprenyl-placebo	1	9.32	(3.10)
	2	5.90	(3.61)
	3	5.31	(3.38)
	4	6.14	(3.46)
	5	1.97	(3.62)
α-Tocopherol-deprenyl	1	2.16	(3.53)
	2	2.82	(3.91)
	3	6.34	(3.09)
	4	5.42	(3.52)
	5	4.86	(3.83)

*Least squares means adjusted for age and gender.

Supplementary Figure 1. Kaplan-Meier estimates of the cumulative probability of reaching the end point by 24 months of follow-up, according to common quintiles of baseline serum urate for all subjects (**A**) and for those treated without (**B**) and with (**C**) α-tocopherol.